| LDR | | 06953cam a2200649 i 4500 |
| 001 | | 000000480279 |
| 005 | | 20230210094508 |
| 006 | | m d |
| 007 | | cr cn||||||||| |
| 008 | | 220202s2021 dcua ob 100 0 eng |
| 016 | 7 |
▼a 9918349844006676
▼2 DNLM |
| 019 | |
▼a 1292356431 |
| 020 | |
▼a 9780309685689 |
| 020 | |
▼a 0309685680 |
| 020 | |
▼a 9780309685719
▼q (electronic bk.) |
| 020 | |
▼a 0309685710
▼q (electronic bk.) |
| 020 | |
▼a 9780309685696
▼q (electronic book) |
| 020 | |
▼a 0309685699
▼q (electronic book) |
| 035 | |
▼a 3133669
▼b (N$T) |
| 035 | |
▼a (OCoLC)1314048550
▼z (OCoLC)1292356431 |
| 040 | |
▼a NLM
▼b eng
▼e rda
▼c NLM
▼d N$T
▼d EBLCP
▼d YDX
▼d 247004 |
| 042 | |
▼a pcc |
| 043 | |
▼a n-us--- |
| 050 | 4 |
▼a RM301.25
▼b .N38 2022 |
| 060 | 00 |
▼a QV 745 |
| 082 | 04 |
▼a 615.19
▼2 23/eng/20220616 |
| 100 | 1 |
▼a Forstag, Erin Hammers,
▼e rapporteur. |
| 245 | 10 |
▼a Drug research and development for adults across the older age span :
▼b proceedings of a workshop/
▼c Erin Hammers Forstag and Carolyn Shore, rapporteurs ; Forum on Aging, Disability, and Independence, Forum on Drug Discovery, Development, and Translation, National Cancer Policy Forum, Board on Health Care Services, Board on Health Sciences Policy, Health and Medicine Division, the National Academies of Sciences, Engineering, Medicine. |
| 264 | 1 |
▼a Washington, DC :
▼b National Academies Press,
▼c [2021] |
| 300 | |
▼a 1 online resource (1 PDF file (xx,122 pages)):
▼b illustrations. |
| 336 | |
▼a text
▼b txt
▼2 rdacontent |
| 337 | |
▼a computer
▼b c
▼2 rdamedia |
| 338 | |
▼a online resource
▼b cr
▼2 rdacarrier |
| 504 | |
▼a Includes bibliographical references. |
| 520 | 3 |
▼a There is a void in evidence-based information for making informed decisions on how to optimize care for older adults, particularly those 80 years and over. Because older adults are vastly underrepresented in clinical trials, there is a dearth of information about the appropriate use of drugs in this population. Yet older adults have higher rates of comorbidities and simultaneous use of multiple medications than the general population, and are the majority users of many medications. Additionally, age-related physiological and pathological changes, particularly for adults 80 years of age and older, can lead to significant differences in the pharmacokinetics (PK)2 and pharmacodynamics (PD)3 of a given drug compared to the general population. On August 5 and 6, 2020, the National Academies of Sciences, Engineering, and Medicine hosted a workshop titled Drug Research and Development for Adults Across the Older Age Span. The workshop was designed to examine the challenges and opportunities in drug research and development for older adult populations, explore barriers that impede safety and efficacy studies in these populations, and share lessons learned for better understanding clinical pharmacology for populations over age 65. This publication summarizes the presentation and discussion of the workshop. |
| 536 | |
▼a This activity was supported by contracts between the National Academy of Sciences and the Administration for Community Living; American Association for Cancer Research; American Association for Retired Persons; American Cancer Society (Contract No. 66383); American College of Radiology; American Geriatrics Society; American Society of Clinical Oncology; Amgen Inc. (Contract No. GHCCOPS-CSARF-175837); Association of American Cancer Institutes; Association of American Medical Colleges; Association of Community Cancer Centers; AstraZeneca; Biogen; Biomedical Advanced Research and Development Authority; Bristol Myers Squibb (Contract No. 57015377); Burroughs Wellcome Fund (Contract No. 1020264); Cancer Support Community; Centers for Disease Control and Prevention (Contract No. 200-2011-38807; Task Order No. 75D30119F00080); CEO Roundtable on Cancer; Consumer Technology Association Foundation; Critical Path Institute; Eli Lilly and Company (Contract No. 4900709231); FasterCures, Milken Institute; Flatiron Health; Foundation for the National Institutes of Health; Friends of Cancer Research; The Gerontological Society of America; GlaxoSmithKline (Contract No. OTH-PPL-32245); The John A. Hartford Foundation; Johnson & Johnson; LeadingAge; Merck & Co., Inc. (Contract Nos. MRLCPO-19-9858 and MRLCPO-19-106723); National Comprehensive Cancer Network; National Institute on Disability, Independent Living, and Rehabilitation Research (Contract No. HHSP233201400020B); National Institutes of Health (Contract No. HHSN263201800029I; Task Order No. HHSN26300007): National Cancer Institute, National Center for Advancing Translational Sciences, National Institute of Allergy and Infectious Diseases, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, Office of Extramural Research, Office of Science Policy; National Institutes of Health (Contract No. HHSN263201800029I; Task Order No. HHSN26300008 and Contract No. HHSN263291800029I; Task Order No. 75N98019F00848): National Institute on Aging; National Patient Advocate Foundation; New England Journal of Medicine; Novartis Oncology (Contract No. NGC38403); Oncology Nursing Society; Paraprofessional Healthcare Institute; Pfizer Inc.; Sanofi (Contract No. 57505685); Society for Immunotherapy of Cancer; Takeda Pharmaceuticals (Contract No. 53108); and U.S. Food and Drug Administration (Grant No. 5R13FD005496-05). Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. |
| 588 | |
▼a Description based on online resource; title from PDF title page (viewed April 27, 2022). |
| 590 | |
▼a WorldCat record variable field(s) change: 050, 082, 650 |
| 650 | 12 |
▼a Drug Development. |
| 650 | 22 |
▼a Pharmacology, Clinical. |
| 650 | 22 |
▼a Clinical Trials as Topic. |
| 650 | 22 |
▼a Aged, 80 and over. |
| 650 | 0 |
▼a Drugs
▼x Research
▼z United States. |
| 651 | 2 |
▼a United States. |
| 655 | 2 |
▼a Congress. |
| 655 | 4 |
▼a Electronic books. |
| 700 | 1 |
▼a Shore, Carolyn,
▼e rapporteur, |
| 710 | 2 |
▼a Forum on Aging, Disability, and Independence,
▼e sponsoring body. |
| 710 | 2 |
▼a National Academies of Sciences, Engineering, and Medicine (U.S.).
▼b Forum on Drug Discovery, Development, and Translation,
▼e sponsoring body. |
| 710 | 2 |
▼a National Cancer Policy Forum (U.S.),
▼e sponsoring body. |
| 711 | 2 |
▼a Drug Research and Development for Adults Across the Older Age Span (Workshop)
▼d (2020 :
▼c Online) |
| 776 | 08 |
▼i Print version:
▼a National Academies of Sciences, Engineering, and Medicine.
▼t Drug Research and Development for Adults Across the Older Age Span.
▼d Washington, D.C. : National Academies Press, 짤2022
▼z 9780309685689 |
| 856 | 40 |
▼3 EBSCOhost
▼u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=3133669 |
| 938 | |
▼a EBSCOhost
▼b EBSC
▼n 3133669 |
| 990 | |
▼a ***1818828 |
| 991 | |
▼a E-BOOK |
| 994 | |
▼a 92
▼b N$T |